Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
7 Prädiktive Pharmakologie und Toxikologie: Genetik, Genomik, Systembiologie
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387–402.
Bertilsson L (2001) Current Status: Pharmacogenetics/Drug Metabolism. In: Kalow W, Meyer UA, Tyndale RF. Pharmacogenomics. Dekker, New York Basel, pp 33–50
Beutler E (1994) G6PD deficiency. Blood 84: 3613–3636
Beutler E, Vulliamy TJ (2002) Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis 28: 93–103
Blackstock WP, Weir MP (1999) Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17: 121–127
Bleumink GS, Schut AF, Sturkenboom MC, Deckers JW, van Duijn CM, Stricker BH (2004) Genetic polymorphisms and heart failure. Genet Med 6:465–474
Borlak J (2005) Handbook of toxicogenomics. Wiley-VCH, Weinheim
Cascorbi I, Paul M, Kroemer HK (2004) Pharmacogenomics of heart failure — focus on drug disposition and action. Cardiovasc Res 64:32–39
Cavalli-Sforza LL, Feldman MV (2003) The application of molecular genetic approaches to the study of human evolution. Nat Genet 33(Suppl): 266–275.
Daly AK, Fairbrother KS, Smart J (1998) Recent advance in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicol Lett 102–103: 143–147
Efferth T, Volm M (2005). Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Therapeutics 107:155–176
Efferth T, Bachli EB, Schwarzl SM, Goede JS, West C, Beutler E (2004) Glucose-6-phosphate dehydrogenase (G6PD) deficiency-type Zurich: a splice site mutation as an uncommon mechanism producing enzyme deficiency. Blood 104: 2608
Efferth T, Sauerbrey A, Steinbach D, Gebhart E, Drexler HG, Miyachi H, Chitambar CR, Becker CM, Humeny A (2003) Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol 23: 509–517
Goedde HW, Agarwal DP (1992) Pharmacogenetics of aldehyde dehydrogenase. In: H Kalow, ed. Pharmacogenetics of drug metabolism. Pergamon, New York, pp 281–311
Gonzalez FJ, Nebert DW (1990) Evolution of the P450 gene superfamily: animalplant ‘warfare’, molecular drive and human genetic differences in drug oxidation. Trends Genet 6: 182–186
Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg S, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594–2601
Harper PA, Wong JY, Lam MS, Okey AB (2002) Polymorphisms in the human AH receptor. Chem Biol Interact 141: 161–187
Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13: 325–349
Kalow W (2001) Interethnic differences in Drug Response. In: Kalow W, Meyer UA, Tyndale RF. Pharmacogenomics. Dekker, New York Basel, pp 109–134
Kalow W and Bertilsson L (1994) Interethnic factors affecting drug response. Adv Drug Res 25: 1–59
Kebarle P, Tang L (1993) From ions in solution to ions in the gas phase — the mechanism of electrospray mass spectrometry. Anal Chem 65: 972A–986A
Kim RB (2002) MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12: 425–427
Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193–202
Marsh S, Kwok P, McLeod HL (2002) SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat 20: 174–179
Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90, 8–11
Montano MM, Ekena K, Keller AL, Katzenellenbogen BS (1996) Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 10: 230–242
Oscarson M (2003) Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Clin Chem Lab Med 41: 573–580.
Pasterkamp G, Van Keulen JK, De Kleijn DP (2004) Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 34: 328–334
Priori SG, Barhanin J, Hauer RN, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM (1999) Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation 99: 674–681
Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS (2004) Association between polymorphisms of ERCC1 and XPD and survival in nonsmall-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311–316.
Sakaeda T, Nakamura T, Okumura K (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4: 397–410
Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM, Psaty BM, Klungel OH (2004) Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 64: 1801–1816
Schwab M, Eichelbaum M, Fromm MF (2003) Genetic polymorphism of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43: 285–307
Schwarzl SM, Smith JC, Kaina B, Efferth T (2005) Molecular modeling of O6-methylguanine-DNA methyltransferase mutant proteins encoded by single nucleotide polymorphisms. Int J Mol Med 16:553–557
Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96: 376–381
Ulrich CM, Robien K, McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3: 912–920
Vink A, de Kleijn DP, Pasterkamp G (2004) Functional role for toll-like receptors in atherosclerosis and arterial remodeling. Curr Opin Lipidol 15: 515–521
Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL (2004) Genomewide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci USA 101: 11809–11814
Weber WW. Pharmacogenetics — Receptors (2001) In: Kalow W, Meyer UA, Tyndale RF. Pharmacogenomics. Dekker, New York Basel, pp 51–80
Weir TD, Mallek N, Sandford AJ, Bai TR, Awadh N, Fitzgerald JM, Cockcroft D, James A, Liggett SB, Pare PD (1992) β2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 158: 787–791
Whitfield JN (1997) Meta-analysis of the effects of alcohol dehydrogenase genotype on alcohol dependence and alcoholic liver disease. Alcohol Alcohol 32: 613–619
Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ (1998) Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 339: 960–965
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2006). Prädiktive Pharmakologie und Toxikologie: Genetik, Genomik, Systembiologie. In: Molekulare Pharmakologie und Toxikologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-48245-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-540-48245-1_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21223-2
Online ISBN: 978-3-540-48245-1
eBook Packages: Life Science and Basic Disciplines (German Language)